INmune Bio Inc
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | 100.0% | – | – | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | – | – | 100.0% | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | 100.0% | – | – | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | – | – | 100.0% | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | 1.1% | – | – | – | 16,900.0% | 62,275.0% | 111,600,000.0% | 46,571.4% | 4,336.2% | 2,643.6% | 26,181.3% | 5,264.3% | 3,515.5% | 10,876.3% | 9,017.4% | 13,918.6% | 21,453.6% | 62,092.9% | – | – | – | 15,278.0% | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | 1.9% | – | – | – | 11,900.0% | 51,200.0% | 52,249,975.0% | 17,964.3% | 1,268.7% | 1,397.5% | 13,506.3% | 2,384.7% | 2,352.6% | 6,013.2% | 5,019.6% | 6,014.0% | 8,571.4% | 16,700.0% | – | – | – | 4,632.0% | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | 3.0% | – | – | – | 29,272.7% | 113,800.0% | 163,850,000.0% | 64,535.7% | 5,639.9% | 4,074.2% | 40,025.0% | 7,694.9% | 5,916.5% | 17,002.6% | 14,037.0% | 19,932.6% | 30,025.0% | 78,792.9% | – | – | – | 19,910.0% | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | -3.0% | – | – | – | -29,172.7% | -113,700.0% | -163,850,000.0% | -64,435.7% | -5,539.9% | -3,974.2% | -39,925.0% | -7,594.9% | -5,816.5% | -16,902.6% | -13,937.0% | -19,832.6% | -29,925.0% | -78,692.9% | – | – | – | -19,810.0% | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 13,073.6% | 260.7% | 2,812.5% | 287.8% | 196.9% | 297.4% | – | – | 403.6% | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | -3.0% | – | – | – | -29,127.3% | -113,900.0% | -166,375,000.0% | -67,557.1% | -5,933.1% | -4,235.0% | -42,737.5% | -7,882.7% | -6,013.4% | -17,200.0% | -14,132.6% | -19,914.0% | -30,028.6% | -78,750.0% | – | – | – | -19,478.0% | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | -3.0% | – | – | – | -29,172.7% | -113,700.0% | -163,850,000.0% | -64,435.7% | 13,073.6% | 260.7% | 2,812.5% | 287.8% | 196.9% | 297.4% | -13,937.0% | -19,832.6% | 52,950.0% | -78,692.9% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | -3.0% | – | – | – | -29,127.3% | -113,900.0% | -166,375,000.0% | -67,557.1% | -5,933.1% | -4,235.0% | -42,737.5% | -7,882.7% | -6,013.4% | -17,200.0% | -14,132.6% | -19,914.0% | -30,028.6% | -78,750.0% | – | – | – | -19,478.0% | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | -3.0% | – | – | – | -29,172.7% | -113,700.0% | -166,375,000.0% | -67,557.1% | 12,680.4% | -3,974.2% | -39,925.0% | -7,594.9% | -5,816.5% | -16,902.6% | -195.7% | -81.4% | -29,925.0% | -78,507.1% | – | – | – | -19,478.0% | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.